Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Total Non-Current Liabilities (2020 - 2025)

Historic Total Non-Current Liabilities for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $367.7 million.

  • Xeris Biopharma Holdings' Total Non-Current Liabilities rose 785.65% to $367.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $367.7 million, marking a year-over-year increase of 785.65%. This contributed to the annual value of $350.7 million for FY2024, which is 806.44% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Total Non-Current Liabilities of $367.7 million as of Q3 2025, which was up 785.65% from $346.2 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' Total Non-Current Liabilities' 5-year high stood at $367.7 million during Q3 2025, with a 5-year trough of $131.8 million in Q3 2021.
  • Over the past 5 years, Xeris Biopharma Holdings' median Total Non-Current Liabilities value was $318.8 million (recorded in 2023), while the average stood at $288.7 million.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Total Non-Current Liabilities soared by 6527.87% in 2022, and later surged by 85.32% in 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Total Non-Current Liabilities (Quarter) stood at $186.6 million in 2021, then soared by 46.65% to $273.6 million in 2022, then increased by 18.6% to $324.5 million in 2023, then increased by 8.06% to $350.7 million in 2024, then grew by 4.83% to $367.7 million in 2025.
  • Its last three reported values are $367.7 million in Q3 2025, $346.2 million for Q2 2025, and $345.7 million during Q1 2025.